Literature DB >> 8640686

The National Cancer Data Base report on longitudinal observations on prostate cancer.

C J Mettlin1, G P Murphy, R Ho, H R Menck.   

Abstract

BACKGROUND: Data on 349,154 prostate cancer cases diagnosed since 1986 have been entered to the American College of Surgeons National Cancer Data Base (NCDB). Previous annual reports have examined subsets of these data. The present report highlights major trends in the presentation and treatment of prostate cancer in the United States evident from longitudinal analyses of the entire data.
METHODS: NCDB data are collected following a computerized, standard format. Hospital participation is voluntary.
RESULTS: Since the first year of data collection, the number of participating hospitals has increased from 496 to 996 and the number of prostate cancer patients reported to the NCDB increased from 19,531 to 84,408. The proportion of men diagnosed at ages younger than 70 years increased from 37.8% in 1986 to 46.9% in 1993. Completeness of reporting stage of disease and tumor grade has improved. The proportions of both the earliest (American joint Committee an Cancer [AJCC] Stage Groups 0 and I) and the most advanced (AJCC++ Stage Group IV) stages declined. The proportion of Grade 2 (moderately differentiated) tumors increased from 38.6% in 1986 to 57.5% in 1993. The proportion of AJCC Stage II prostate cancer increased from 19% in 1986 to 48.4% in 1993. The proportion of patients treated by prostatectomy increased from 9.9% in 1986 to 29.2% in 1993. The proportion of patients receiving no cancer directed treatment declined from 41.8% in 1986 to 21.6% in 1993. Less change was observed in the use of radiation and hormonal treatments.
CONCLUSIONS: These data show that the clinical patterns of prostate cancer have changed markedly in recent years.

Entities:  

Mesh:

Year:  1996        PMID: 8640686     DOI: 10.1002/(SICI)1097-0142(19960515)77:10<2162::AID-CNCR30>3.0.CO;2-R

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Patterns of prostate cancer treatment by clinical stage and age.

Authors:  D Meltzer; B Egleston; I Abdalla
Journal:  Am J Public Health       Date:  2001-01       Impact factor: 9.308

2.  Prostate cancer survival in Trinidad: Is PSA a prognostic factor?

Authors:  Kameel Mungrue; Suresh Moonan; Maryam Mohammed; Saara Hyatali
Journal:  Can Urol Assoc J       Date:  2011-11-02       Impact factor: 1.862

3.  Randomized studies of PSA screening: an opinion.

Authors:  Oliver Sartor
Journal:  Asian J Androl       Date:  2011-02-28       Impact factor: 3.285

4.  Evaluation and treatment of men with biochemical prostate-specific antigen recurrence following definitive therapy for clinically localized prostate cancer.

Authors:  C R Pound; M K Brawer; A W Partin
Journal:  Rev Urol       Date:  2001

5.  The correlation of extent and grade of inflammation with serum PSA levels in patients with IV prostatitis.

Authors:  Li Gui-Zhong; Man Libo; Huang Guanglin; Wang Jianwei
Journal:  Int Urol Nephrol       Date:  2010-09-05       Impact factor: 2.370

6.  The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Authors:  S A Grover; L Coupal; H Zowall; R Rajan; J Trachtenberg; M Elhilali; M Chetner; L Goldenberg
Journal:  CMAJ       Date:  2000-04-04       Impact factor: 8.262

7.  The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model.

Authors:  S A Grover; L Coupal; H Zowall; R Rajan; J Trachtenberg; M Elhilali; M Chetner; L Goldenberg
Journal:  CMAJ       Date:  2000-04-04       Impact factor: 8.262

Review 8.  Prostate cancer, Incidence, management and outcomes.

Authors:  E J Small
Journal:  Drugs Aging       Date:  1998-07       Impact factor: 3.923

Review 9.  Prostate-specific antigen and related isoforms in the diagnosis and management of prostate cancer.

Authors:  Alexander Haese; Markus Graefen; Hartwig Huland; Hans Lilja
Journal:  Curr Urol Rep       Date:  2004-06       Impact factor: 3.092

Review 10.  What does prostate-specific antigen recurrence mean?

Authors:  C R Pound; A W Partin
Journal:  Curr Urol Rep       Date:  2000-05       Impact factor: 2.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.